Investors dump Juno on clinical hold

Juno Therapeutics Inc. (NASDAQ:JUNO) fell 32% on Friday, as investors sold on late Thursday's news that FDA placed a clinical hold on the Phase II ROCKET trial of JCAR015 following two patient deaths from cerebral edema. The stock fell $13.01 to $27.81, shedding $1.4 billion in market cap to $2.9 billion.

Fellow T cell immunotherapy company Kite Pharma Inc. (NASDAQ:KITE) was down $3.57 to $48.53, closing the week with a market cap of $2.4 billion. ...